Palisade Bio PALI
NASDAQ PALI
$2.09 +0.04 (+2.20%)
At close: Sep 4, 2026 · 4:00 PM EDT

Palisade Bio (PALI) Short term Debt (2013 - 2025)

Palisade Bio (PALI) posted quarterly Short term Debt of $235000.0 for Q3 2025, up 256.06% quarter-over-quarter from $66000.0 in Q2 2025.

Analysis

Palisade Bio (PALI) Short term Debt (2013 - 2025) Analysis & Trends

Palisade Bio (PALI) has reported Short term Debt for 10 consecutive years, with $235000.0 the latest figure, recorded in Q3 2025.

  • In Q3 2025, Short term Debt changed N/A year-over-year to $235000.0; the TTM figure through Sep 2025 stood at $235000.0 (changed N/A YoY), while the FY2023 annual figure was $143000.0, changed N/A from the prior year.
  • Short term Debt improved to $235000.0 in Q3 2025 per PALI's latest filing, from $66000.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $1.1 million in Q2 2021 and bottomed at $66000.0 in Q2 2025.
  • Historically, Short term Debt has averaged $254125.0 across 4 years, with a median of $143000.0 in 2023.
  • Annual changes were most pronounced in 2021 — Short term Debt sank 91.69% — and 2025, when it tumbled 51.75%.
  • Palisade Bio's Short term Debt stood at $87000.0 in 2021, then jumped by 64.37% to $143000.0 in 2023, then gained by 4.2% to $149000.0 in 2024, then surged by 57.72% to $235000.0 in 2025.
  • Business Quant data shows PALI's Short term Debt at $235000.0 in Q3 2025, $66000.0 in Q2 2025, and $69000.0 in Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Palisade Bio 440.73 Mn 315.53 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 235,000.00
Jun 30, 2025 66,000.00
Mar 31, 2025 69,000.00
Jun 30, 2024 149,000.00
Mar 31, 2024 143,000.00
Dec 31, 2023 143,000.00
Dec 31, 2021 87,000.00
Jun 30, 2021 1.14 Mn
Dec 31, 2020 1.05 Mn
Mar 31, 2017 2.53 Mn
Dec 31, 2016 3.71 Mn
Sep 30, 2016 4.83 Mn
Jun 30, 2016 5.91 Mn
Mar 31, 2016 4.47 Mn
Dec 31, 2015 4.55 Mn
Sep 30, 2015 4.46 Mn
Jun 30, 2015 3.17 Mn
Mar 31, 2015 1.93 Mn
Dec 31, 2014 730,012.00
Sep 30, 2014 3.06 Mn